RBPJ and MAML3: Potential therapeutic targets for small cell lung cancer

Hideya Onishi, Shu Ichimiya, Kosuke Yanai, Masayo Umebayashi, Katsuya Nakamura, Akio Yamasaki, Akira Imaizumi, Shuntaro Nagai, Mutsunori Murahashi, Hisanobu Ogata, Takashi Morisaki

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)


Background/Aim: Small cell lung cancer (SCLC) is still a deadly type of cancer for which there are few effective therapeutic strategies. Development of a new molecule targeting agent is urgently desired. Previously we showed that recombination signal binding protein for immunoglobulin-kappa-J region (RBPJ) and mastermindlike 3 (MAML3) are new therapeutic targets for pancreatic cancer. In the present study, we analyzed whether RBPJ/MAML3 inhibition could also be a new therapeutic strategy for SCLC. Materials and Methods: Using silencing of RBPJ/MAML3, proliferation, invasion, migration and chemosensitivity of SBC-5 cells were investigated. Results: RBPJ/MAML3 inhibition reduced Smoothened and HES1 expression, suggesting that RBPJ/MAML3 signaling was through Hedgehog and NOTCH pathways. In the analysis of cell functions, RBPJ/MAML3 inhibition significantly reduced proliferation and invasiveness via reduction of expression of matrix metalloproteinases. On the other hand, RBPJ/MAML3 inhibition also reduced chemosensitivity to cis-diamminedichlo-roplatinum and gemcitabine. Conclusion: These results suggest that RBPJ and MAML3 could be new therapeutic targets for SCLC, however, chemosensitivity may be reduced in combinational use with other chemo-therapeutic agents.

Original languageEnglish
Pages (from-to)4543-4547
Number of pages5
JournalAnticancer research
Issue number8
Publication statusPublished - Aug 2018

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'RBPJ and MAML3: Potential therapeutic targets for small cell lung cancer'. Together they form a unique fingerprint.

Cite this